Where I see patients (2)
Risk Factors for a Higher Symptom Burden in Patients With Cancer During the COVID-19 Pandemic.
Oncology nursing forum
Systemic Therapy for Melanoma: ASCO Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
COVID-19 pandemic stress and cancer symptom burden.
BMJ supportive & palliative care
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignanci...
Assess the safety and tolerability of single-agent RP1 in solid organ transplant patients with cutaneous malignancies by incidence of subjects with treatment-emergent adverse events
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NS...
Assess dose limiting toxicity as defined in the protocol
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) as a monotherapy and in combination therapy in Part A and Part B
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Percentage of subjects with adverse events (AEs)